GNTA (Genenta Science) נזילות מהירה

Genenta Science S.p.A. (GNTA) holds a leading position in developing treatments for solid tumors, utilizing lentiviral vectors for targeted drug delivery. Price visualization on GURU.Markets, where the indicator stands at 13.67, links these achievements to the business's dependence on glioblastoma therapy outcomes and the safety of cellular transport. High authority among oncologists and a flawless image make the company attractive to investors.

This ratio measures the company's ability to cover short-term liabilities using its most liquid assets, completely excluding inventory from the calculation. By analyzing the liquidity ratio without non-liquid assets for Genenta Science (GNTA), an investor assesses the financial stability of an R&D startup whose costs are concentrated in laboratories and bio-waste disposal, which minimizes overstocking risks and emphasizes the importance of cash flow management.